{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T08:00:38Z","timestamp":1762761638944,"version":"3.41.2"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,2,25]],"date-time":"2020-02-25T00:00:00Z","timestamp":1582588800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2020.00192","type":"journal-article","created":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T23:54:32Z","timestamp":1582588472000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Clinico-Immunological Profile of a 67-Year-Old Woman Affected by HER2-Positive Breast Cancer and Autoimmune Dermatomyositis"],"prefix":"10.3389","volume":"10","author":[{"given":"Benedetta","family":"Pellegrino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Mazzaschi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denise","family":"Madeddu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Costanza Anna Maria","family":"Lagrasta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriele","family":"Missale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Quaini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonino","family":"Musolino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,2,25]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ctrv.2015.11.010","article-title":"Prognostic risk factors for treatment decision in pT1a,b N0M0 HER2-positive breast cancers","volume":"43","author":"Musolino","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e58","DOI":"10.1016\/S1470-2045(13)70477-7","article-title":"The immune system and response to HER2-targeted treatment in breast cancer","volume":"15","author":"Bianchini","year":"2014","journal-title":"Lancet Oncol"},{"key":"B4","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1001\/archderm.1980.01640270055013","article-title":"The relationship of dermatomyositis and polymyositis to internal malignancy","volume":"116","author":"Callen","year":"1980","journal-title":"Arch Dermatol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1111\/j.1365-2133.2004.06144.x","article-title":"Infiltrating cells, related cytokines and chemokine receptors in lesional skin of patients with dermatomyositis","volume":"151","author":"Caproni","year":"2004","journal-title":"Br J Dermatol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.1002\/art.38137","article-title":"Genome-wide association study of dermatomyositis reveals genetic overlap with other autoimmune disorders","volume":"65","author":"Miller","year":"2013","journal-title":"Arthritis Rheum"},{"key":"B7","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/S0140-6736(00)03540-6","article-title":"Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study","volume":"357","author":"Hill","year":"2001","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.chemosphere.2012.12.037.Reactivity","article-title":"Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib and trastuzumab: a secondary analysis of the NeoALTTO Trial","volume":"91","author":"Salgado","year":"2015","journal-title":"JAMA Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"3798","DOI":"10.1200\/JCO.2003.11.069","article-title":"Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis","volume":"21","author":"Hirsch","year":"2003","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1038\/onc.2009.197","article-title":"Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors","volume":"28","author":"John","year":"2009","journal-title":"Oncogene"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.3390\/cancers11071033","article-title":"PD-1\/PD-L1 targeting in breast cancer: the first clinical evidences are emerging. A literature review","volume":"11","author":"Planes-Laine","year":"2019","journal-title":"Cancers"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e429","DOI":"10.3747\/co.24.3696","article-title":"Breast cancer and dermatomyositis: a case study and literature review","volume":"24","author":"Hendren","year":"2017","journal-title":"Curr Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1093\/annonc\/mdw262","article-title":"Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-Positive breast cancer patients treated with chemotherapy and HER2-Targeted agents in the CherLOB trial","volume":"27","author":"Dieci","year":"2016","journal-title":"Ann Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1093\/annonc\/mdv239","article-title":"Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials","volume":"26","author":"Dieci","year":"2015","journal-title":"Ann Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13058-018-0989-8","article-title":"Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer","volume":"20","author":"Norton","year":"2018","journal-title":"Breast Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.autrev.2009.12.005","article-title":"Polymyositis, dermatomyositis and malignancy: a further intriguing link","volume":"9","author":"Zampieri","year":"2010","journal-title":"Autoimmun Rev"},{"key":"B17","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/s11912-017-0627-0","article-title":"Immunotherapy in breast cancer: the emerging role of PD-1 and PD-L1","volume":"19","author":"Bertucci","year":"2017","journal-title":"Curr Oncol Rep"},{"key":"B18","doi-asserted-by":"publisher","first-page":"v104","DOI":"10.1093\/annonc\/mdz242","article-title":"305O. Overall survival (OS) in KATE2, a phase II study of programmed death ligand 1 (PD-L1) inhibitor atezolizumab (atezo)+trastuzumab emtansine (T-DM1) vs placebo (pbo)+T-DM1 in previously treated HER2+ advanced breast cancer (BC)","volume":"30","author":"Emens","year":"2019","journal-title":"Ann Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/ni1443","article-title":"The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection","volume":"8","author":"Sharpe","year":"2007","journal-title":"Nat Immunol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.00192\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T23:54:34Z","timestamp":1582588474000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.00192\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,25]]},"references-count":19,"alternative-id":["10.3389\/fonc.2020.00192"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2020.00192","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2020,2,25]]},"article-number":"192"}}